Comprehensive Gouty Arthritis Market Forecast 2025-2034: Growth Trends and Strategic Shifts

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Gouty Arthritis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The financial scope of the gouty arthritis sector has experienced considerable expansion recently, projecting an increase from a valuation of $3.44 billion in the year 2024 to $3.69 billion by 2025, signifying a compound annual growth rate (CAGR) of 7.3%. This robust expansion observed over the past years stems from several key factors, including the widespread presence of long-term illnesses, greater consumption of alcoholic beverages, a demographic shift toward an older population, the increasing adoption of advanced regenerative treatments, and escalating spending within the healthcare domain.

Gouty Arthritis Market Size Forecast: What's the Projected Valuation by 2029?
Anticipated for the near future is considerable expansion within the gouty arthritis market, projecting a valuation reaching 4.8 billion US dollars by 2029, underpinned by a compound annual growth rate (CAGR) of 6.8%. This forward trajectory in growth is largely fueled by advances in medical infrastructure, rising rates of obesity, a greater prevalence of gout diagnoses, and heightened public consciousness regarding the condition. Key developments set to shape this market sector during the forecast timeframe encompass the escalating need for successful therapeutic interventions, the emergence of regenerative treatments, strides in technology, fresh product introductions, and the attainment of necessary regulatory clearances.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gouty-arthritis-global-market-report

What Are the Drivers Transforming the Gouty Arthritis Market?
The escalating incidence of obesity is anticipated to serve as a significant catalyst for the expansion of the gouty arthritis market moving ahead. Obesity, defined as an excessive accumulation of body fat that compromises an individual's well-being and is often quantified via the body mass index (BMI), is on the rise, primarily attributed to greater intake of energy-dense, refined foodstuffs and inactive ways of living. This excess weight promotes gouty arthritis because it elevates uric acid generation while simultaneously impairing the body's mechanism for its elimination, causing uric acid crystals to deposit in the joints. Moreover, the added strain from carrying extra weight intensifies the joint stress, worsening the pain and inflammation characteristic of gout. To illustrate this trend, data released in March 2022 by the World Health Organization, the global health authority within the United Nations structure and based in Switzerland, indicated that roughly one billion people globally-including 650 million adults, 340 million adolescents, and 39 million youngsters-were categorized as obese, a number still climbing. Moreover, forecasts suggest that by the year 2025, roughly 167 million children and adults will contend with associated health issues stemming from being overweight. Consequently, this growing trend in obesity levels directly fuels the progression of the gouty arthritis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16070&type=smp

What Long-Term Trends Will Define the Future of the Gouty Arthritis Market?
Leading firms within the gouty arthritis sector are intensifying their focus on innovating new therapeutic agents, exemplified by cortrophin gel, aiming to deliver superior and precise treatments for managing this ailment. Cortrophin gel, alternatively termed repository corticotropin injection, represents a refined preparation of adrenocorticotropic hormone (ACTH), and it finds application in addressing a spectrum of inflammatory and autoimmune disorders, gouty arthritis being one such condition. To illustrate, a significant regulatory milestone occurred in October 2023 when ANI Pharmaceuticals, a company based in the United States, secured clearance from the Food and Drug Administration for introducing a new 1-mL vial presentation of Purified Cortrophin Gel, specifically designed as an add-on therapy for select individuals undergoing acute exacerbations of gouty arthritis. Presently, Cortrophin Gel holds the distinction of being the exclusive ACTH therapy endorsed by the FDA for the treatment of suitable candidates suffering from acute gouty arthritis flares.

Which Segments in the Gouty Arthritis Market Offer the Most Profit Potential?
The gouty arthritismarket covered in this report is segmented -

1) By Type: Acute Gouty Arthritis; Chronic Gouty Arthritis
2) By Treatment: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Pain Reliever; Corticosteroids; Xanthine Oxidase Inhibitors; Uricosurics; Others Treatments
3) By Diagnosis: Joint Fluid Test; Blood Test; X-Ray Imaging; Ultrasound; Dual Energy Computed Tomography (CT) Scan; Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Others Distribution Channels
5) By End-Users: Hospitals; Specialty Clinics; Other End-Users

Subsegments:
1) By Acute Gouty Arthritis: Monosodium Urate Crystals-Induced Acute Gout; Acute Gout Attack (Intermittent Flares); Severe Acute Gout With Joint Deformities
2) By Chronic Gouty Arthritis: Tophaceous Gout (Presence Of Uric Acid Deposits); Chronic Gout With Joint Damage; Chronic Gout With Renal Complications; Chronic Gout With Comorbidities (Hypertension, Diabetes)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16070&type=smp

Which Firms Dominate the Gouty Arthritis Market by Market Share and Revenue in 2025?
Major companies operating in the gouty arthritis market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol Myers Squibb, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Horizon Therapeutics plc, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc.

Which Regions Offer the Highest Growth Potential in the Gouty Arthritis Market?
North America was the largest region in the gouty arthritis market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the gouty arthritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16070

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.